A BROAD RANGE OF CMC EXPERTISE

There are times when training alone is not sufficient. Gain guidance from experienced experts, who were pionneers in antibody discovery and on the field of process development and validation for decades to launch new biological entities, including biosimilars. Talabardon Consulting will assist you in your CMC projects, from mammalian cells, yeasts or bacteria cultures, for gene & cell therapy, ATMP, antibody or any other large molecules. The following are our main specific areas of deep expertise.

Drug Substance

large molecule biologics

glycosylated molecules

process design

fed-batch, perfusion upstream process

continuous upstream & downstream process

technical transfer & scale-up

risk assessments

scale-down model qualification

process troubleshooting

stage 1 process characterisation

stats & design space

stage 2 Process qualification

stage 3 Continued Process Verification

Quality by Design (QbD)

Prior knowledge

LCM, process optimisation

selection of critical quality attributes

specifications

mammalian cell culture , microbial fermentation

cell & gene therapy

Analytical methods

Drug Product

formulation development

process characterisation

process qualification

CPV - Life Cycle Management

product characterisation

product release

shelf life

specs at release and end of shelf life

product stability

process optimisation

process troubleshooting

product sterility

prior knowledge

analytical methods

Regulatory Affairs

CMC regulatory Strategy & guidance (Module 3)

early-stage, late-stage and marketing approval

FDA, EMA & other agencies

submission management & publishing

IND/IMPD, BLA/MAA

post-approval supplements

CMC package for accelerated programs for breakthrough therapies

Cell Banking

cell line development

monoclonality

establishment of RCB, MCB, WCB, EoPCB, LIVCA

cell bank system qualification

cell banks for Bioassays

process design

testing requirements

Biosimilars

biosimilarity with originator

process development

differences in CMC activities compared to NBE

specifications set-up

specific regulatory requirements

statistical analysis for biosimilars only

Safety for Patients

Raw materials testings

Cell banking testings

risk assessments

toxicity assessment

viral clearance studies

analyticals

control strategy

testing plan

DP sterility